Evidence map›Paper›PMID 34906074›Full record

ArticleMolecular medicine (Cambridge, Mass.)2021

Rab31-dependent regulation of transforming growth factor ß expression in breast cancer cells.

Susanne Soelch, Nathalie Beaufort, Daniela Loessner, Matthias Kotzsch, Ute Reuning, Thomas Luther, Thomas Kirchner, Viktor Magdolen

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Susanne SoelchClinical Research Unit, Department of Obstetrics and Gynecology, Technische Universität München, Ismaninger Str. 22, 81576, Munich, Germany.
Nathalie BeaufortInstitute for Stroke and Dementia Research, Klinikum Der Universität München, Munich, Germany.
Daniela LoessnerLeibniz-Institut für Polymerforschung Dresden e.V, Dresden, Germany.
Matthias KotzschMedizinisches Labor Ostsachsen, Dresden, Germany.
Ute ReuningClinical Research Unit, Department of Obstetrics and Gynecology, Technische Universität München, Ismaninger Str. 22, 81576, Munich, Germany.
Thomas LutherMedizinisches Labor Ostsachsen, Dresden, Germany.
Thomas Kirchner *Medizinisches Labor Ostsachsen, Dresden, Germany.
Viktor Magdolen *Clinical Research Unit, Department of Obstetrics and Gynecology, Technische Universität München, Ismaninger Str. 22, 81576, Munich, Germany. viktor.magdolen@tum.de.ORCID 0000-0003-0167-793X
Labor Pachmann · DETechnical University of Munich · DELeibniz Institute of Polymer Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe small GTP-binding protein Rab31 plays an important role in the modulation of tumor biological-relevant processes, including cell proliferation, adhesion, and invasion. As an underlying mechanism, Rab31 is presumed to act as a molecular switch between a more proliferative and an invasive phenotype. This prompted us to analyze whether Rab31 overexpression in breast cancer cells affects expression of genes involved in epithelial-to-mesenchymal transition (EMT)-like processes when compared to Rab31 low-expressing cells.

methodsCommercially available profiler PCR arrays were applied to search for differentially expressed genes in Rab31 high- and low-expressing CAMA-1 breast cancer cells. Differential expression of selected candidate genes in response to Rab31 overexpression in CAMA-1 cells was validated by independent qPCR and protein assays.

resultsGene expression profiling of key genes involved in EMT, or its reciprocal process MET, identified 9 genes being significantly up- or down-regulated in Rab31 overexpressing CAMA-1 cells, with the strongest effects seen for TGFB1, encoding TGF-ß1 (> 25-fold down-regulation in Rab31 overexpressing cells). Subsequent validation analyses by qPCR revealed a strong down-regulation of TGFB1 mRNA levels in response to increased Rab31 expression not only in CAMA-1 cells, but also in another breast cancer cell line, MDA-MB-231. Using ELISA and Western blot analysis, a considerable reduction of both intracellular and secreted TGF-ß1 antigen levels was determined in Rab31 overexpressing cells compared to vector control cells. Furthermore, reduced TGF-ß activity was observed upon Rab31 overexpression in CAMA-1 cells using a sensitive TGF-ß bioassay. Finally, the relationship between Rab31 expression and the TGF-ß axis was analyzed by another profiler PCR array focusing on genes involved in TGF-ß signaling. We found 12 out of 84 mRNAs significantly reduced and 7 mRNAs significantly increased upon Rab31 overexpression.

conclusionsOur results demonstrate that Rab31 is a potent modulator of the expression of TGF-ß and other components of the TGF-ß signaling pathway in breast cancer cells.

Indexed as

Breast NeoplasmsCell Line, TumorEpithelial-Mesenchymal TransitionFemaleHumansrab GTP-Binding ProteinsTransforming Growth Factor beta1RAB31 protein, humanrab GTP-Binding ProteinsTGFB1 protein, humanTransforming Growth Factor beta1Breast cancerEMTGTPaseRab31TGF-ß signaling

Identifiers

PMID34906074
PMCPMC8670132
OpenAlexW4200040704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.